M&T Bank’s Apellis Pharmaceuticals APLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-11,049
Closed -$444K – 1783
2026
Q1
$444K Sell
11,049
-3,428
-24% -$73.9K ﹤0.01% 1185
2025
Q4
$364K Buy
14,477
+1,452
+11% +$34.1K ﹤0.01% 1280
2025
Q3
$296K Buy
+13,025
New +$304K ﹤0.01% 1219
2025
Q1
– Sell
-6,768
Closed -$216K – 1560
2024
Q4
$216K Buy
+6,768
New +$204K ﹤0.01% 1504
2024
Q3
– Sell
-6,820
Closed -$262K – 1631
2024
Q2
$262K Buy
6,820
+1,549
+29% +$70.2K ﹤0.01% 1368
2024
Q1
$310K Buy
5,271
+591
+13% +$37.7K ﹤0.01% 1310
2023
Q4
$280K Buy
+4,680
New +$237K ﹤0.01% 1345

Other funds holding APLS

M&T Bank's APLS Position: Q2 2026 in Review

M&T Bank sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 11,049 shares — an estimated $444K sold.

M&T Bank first reported a position in APLS in Q4 2023 and held it in 7 quarters. The position peaked at $444K in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • M&T Bank reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • M&T Bank sold 11,049 Apellis Pharmaceuticals shares in Q2 2026, an estimated $444K.
  • M&T Bank first reported a position in Apellis Pharmaceuticals in Q4 2023 and held it in 7 quarters.
  • M&T Bank's Apellis Pharmaceuticals position peaked at $444K in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on M&T Bank's 13F filing for Q2 2026, filed 4 Aug 2026.